George T. Chen

George T. Chen

Auto-generated profile, based on publicly available information

George T. Chen

Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Nature
Verified
Journal Article
Open access
PDF file
MGMichael J. Gandal
Michael J. Gandal
JHJillian R. Haney
Jillian R. Haney
BWBrie Wamsley
Brie Wamsley
CYChloe X. Yap
Chloe X. Yap
SPSepideh Parhami
Sepideh Parhami
Daniel GeschwindDaniel Geschwind
Daniel Geschwind
Neuropsychiatric disorders classically lack defining brain pathologies, but recent work has demonstrated dysregulation at the molecular level, characterized by transcriptomic and epigenetic alterations1–3. In autism spectrum disorder (ASD), this molecular pathology involves the upregulation of microglial, astrocyte and neural–immune genes, the downregulation of synaptic genes, and attenuation of gene-expression gradients in cortex1,2,4–6. However, whether these changes are limited to cortical association regions or are more widespread remains unknown. To address this issue, we performed RNA-sequencing analysis of 725 brain samples spanning 11 cortical areas from 112 post-mortem samples from individuals with ASD and neurotypical controls. We find widespread transcriptomic changes across the cortex in ASD, exhibiting an anterior-to-posterior gradient, with the greatest differences in primary visual cortex, coincident with an attenuation of the typical transcriptomic differences between cortical regions. Single-nucleus RNA-sequencing and methylation profiling demonstrate that this robust molecular signature reflects changes in cell-type-specific gene expression, particularly affecting excitatory neurons and glia. Both rare and common ASD-associated genetic variation converge within a downregulated co-expression module involving synaptic signalling, and common variation alone is enriched within a module of upregulated protein chaperone genes. These results highlight widespread molecular changes across the cerebral cortex in ASD, extending beyond association cortex to broadly involve primary sensory regions.

5 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SZSuping Zhang
Suping Zhang
LCLiguang Chen
Liguang Chen
BCBing Cui
Bing Cui
HCHan-Yu Chuang
Han-Yu Chuang
JYJianqiang Yu
Jianqiang Yu
TKThomas Kipps
Thomas Kipps
Receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) is expressed during embryogenesis and by certain leukemias, but not by normal adult tissues. Here we show that the neoplastic cells of many human breast cancers express the ROR1 protein and high-level expression of ROR1 in breast adenocarcinoma was associated with aggressive disease. Silencing expression of ROR1 in human breast cancer cell lines found to express this protein impaired their growth in vitro and also in immune-deficient mice. We found that ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth. Wnt5a, a ligand of ROR1, could induce ROR1-dependent signaling and enhance cell growth. This study demonstrates that ROR1 is expressed in human breast cancers and has biological and clinical significance, indicating that it may be a potential target for breast cancer therapy.

19 February 2021 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
SHStephanie Hachey
Stephanie Hachey
SMSilva Movsesyan
Silva Movsesyan
QNQuy H. Nguyen
Quy H. Nguyen
GBGiselle Burton-Sojo
Giselle Burton-Sojo
ATAni Tankazyan
Ani Tankazyan
CHChristopher C. W. Hughes
Christopher C. W. Hughes
Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening and disease modeling tools. The vascularized micro-tumor (VMT) is a novel three-dimensional model system (tumor-on-a-chip) that recapitulates the complex human tumor microenvironment, including perfused vasculature, within a transparent microfluidic device, allowing real-time study of drug responses and tumor–stromal interactions. Here we have validated this microphysiological system (MPS) platform for the study of colorectal cancer (CRC), the second leading cause of cancer-related deaths, by showing that gene expression, tumor heterogeneity, and treatment responses in the VMT more closely model CRC tumor clinicopathology than current standard drug screening modalities, including 2-dimensional monolayer culture and 3-dimensional spheroids.

24 August 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
YLYung Lyou
Yung Lyou
AHAmber N Habowski
Amber N Habowski
GCGeorge T Chen
George T Chen
MWMarian L Waterman
Marian L Waterman

1 February 2017 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
MLMary Lee
Mary Lee
GCGeorge T Chen
George T Chen
EPEric Puttock
Eric Puttock
KWKehui Wang
Kehui Wang
RERobert A Edwards
Robert A Edwards
JLJohn Lowengrub
John Lowengrub
Cell‐intrinsic metabolic reprogramming is a hallmark of cancer that provides anabolic support to cell proliferation. How reprogramming influences tumor heterogeneity or drug sensitivities is not well understood. Here, we report a self‐organizing spatial pattern of glycolysis in xenograft colon tumors where pyruvate dehydrogenase kinase (PDK1), a negative regulator of oxidative phosphorylation, is highly active in clusters of cells arranged in a spotted array. To understand this pattern, we developed a reaction–diffusion model that incorporates Wnt signaling, a pathway known to upregulate PDK1 and Warburg metabolism. Partial interference with Wnt alters the size and intensity of the spotted pattern in tumors and in the model. The model predicts that Wnt inhibition should trigger an increase in proteins that enhance the range of Wnt ligand diffusion. Not only was this prediction validated in xenograft tumors but similar patterns also emerge in radiochemotherapy‐treated colorectal cancer. The model also predicts that inhibitors that target glycolysis or Wnt signaling in combination should synergize and be more effective than each treatment individually. We validated this prediction in 3D colon tumor spheroids.

14 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GCGeorge T. Chen
George T. Chen
GNGayatri Nair
Gayatri Nair
AOAubrey J. Osorio
Aubrey J. Osorio
SHSandra M. Holley
Sandra M. Holley
KGKimiya Ghassemzadeh
Kimiya Ghassemzadeh
Daniel GeschwindDaniel Geschwind
Daniel Geschwind
Autism Spectrum Disorder (ASD) is a highly heritable condition with diverse clinical presentations. Approximately 20% of ASD’s genetic susceptibility is imparted by de novo mutations of major effect, most of which cause haploinsufficiency. We mapped enhancers of two high confidence autism genes – CHD8 and SCN2A and used CRISPR-based gene activation (CRISPR-A) in hPSC-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency, taking advantage of the presence of a wildtype allele of each gene and endogenous gene regulation. We found that CRISPR-A induced a sustained increase in CHD8 and SCN2A expression in neurons and organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology. These data support gene activation via targeting enhancers of haploinsufficient genes as a therapeutic intervention in ASD and other neurodevelopmental disorders.